A Phase IV, Randomized, Double-Blind Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis) in Children at High Risk for the Development of Serious RSV Disease
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- Sponsors MedImmune
- 27 Oct 2008 Primary outcome changed as reported by ClinicalTrials.gov.
- 27 Oct 2008 Actual patient number (417) added as reported by ClinicalTrials.gov.
- 07 Aug 2008 New trial record.